Go Deep
SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -22,195 | -0.5 | -6.46 | 1.56 | 28.45 |
SymBio Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 236,501,000.0 | 233,463,000.0 | 336,840,000.0 | 324,170,000.0 |
| Net Profit | -1,218,525,000.0 | -2,401,405,000.0 | -1,210,539,000.0 | -1,196,465,000.0 |
| EPS | — | -35.9 | — | — |
SymBio Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 1,307,648,000.0 | 2,452,912,000.0 | 5,589,708,000.0 | 10,008,338,000.0 | — |
| Net Profit | -4,776,194,000.0 | -3,833,480,000.0 | -1,962,817,000.0 | 1,179,238,000.0 | — |
| EPS | -95.1 | -85.0 | -49.2 | 30.2 | — |
SymBio Pharmaceuticals Limited Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 3,867,316,000.0 | 4,968,333,000.0 | 8,170,243,000.0 | 10,433,347,000.0 | — |
| Total Liabilities | 2,595,277,000.0 | 770,774,000.0 | 960,333,000.0 | 1,927,256,000.0 | — |
| Total Equity | 1,272,039,000.0 | 4,197,559,000.0 | 7,209,910,000.0 | 8,506,091,000.0 | — |
Owes vs Owns
SymBio Pharmaceuticals Limited owed ¥1.31 for every ¥1 it owned in Jun 2026, up from ¥0.18 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.31× | 0.67× | 0.16× | 0.12× | 0.18× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
SymBio Pharmaceuticals Limited Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 74.6%Receivables 6.7%Inventory 7.5%Fixed assets (tangible) 1.0%Other assets 10.3%
How it's funded — Dec 2025
Short-term debt 17.6%Long-term debt 33.6%Payables 15.2%Other liabilities 0.7%Shareholders' equity 32.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,883.5 | 3,963.6 | 6,517.0 | 6,282.6 |
| Receivables | 259.7 | 423.2 | 913.1 | 2,084.9 |
| Inventory | 288.9 | 238.9 | 232.0 | 469.4 |
| Fixed assets (tangible) | 37.3 | 44.1 | 87.7 | 153.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 222.2 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 397.8 | 298.6 | 420.4 | 1,220.6 |
| Liabilities & equity | ||||
| Short-term debt | 682.5 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 1,300.0 | 0.0 | 0.0 | 0.0 |
| Payables | 586.8 | 737.9 | 0.0 | 46.6 |
| Other liabilities | 26.0 | 32.9 | 960.3 | 1,880.6 |
| Shareholders' equity | 1,272.0 | 4,197.6 | 7,209.9 | 8,506.1 |
| Net tangible assets | 1,272.0 | 4,197.6 | 7,209.9 | 8,283.9 |
SymBio Pharmaceuticals Limited Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -4,575,568,000.0 | -3,416,518,000.0 | -194,685,000.0 | 1,614,241,000.0 | — |
| Investing Activities | -75,916,000.0 | -3,955,000.0 | -376,696,000.0 | -47,127,000.0 | — |
| Financing Activities | 3,621,610,000.0 | 708,472,000.0 | 680,160,000.0 | 627,985,000.0 | — |